On the morning of October 15, the CPC Committee Secretary of Anhui Province and Chairman of Standing Committee of Provincial People's Congress Zhang Baoshun inspected and investigated on CR Jinchan Pharmaceuticals Co. Ltd. in Anhui Province, accompanied by leaders as Huaibei Municipal CPC Secretary Xiao Chaoying and Deputy Municipal CPC Secretary and Mayor Huang Xiaowu.

Zhang and his delegation listened to the report on the enterprise development, product R&D, internationalized cooperation and construction of modern Chinese medicine park and learned about the basic situation of CR Jinchan Pharmaceuticals. He encouraged CR to take full advantage of its capital, technology and talents to promote independent innovation, speed up the transformation from technology to productivity, continuously raising the quality and efficiency of enterprise development and keep the enterprise’s harmony and stability.

CR Jinchan Pharmaceuticals Co. Ltd is a subsidiary of CR Sanjiu. Its leading product China Cinobufotalin under the brand “Jinchan (Gold Cinobufotalin)” is a pure Chinese medicine with the main raw material of indigenous Chinese herb--the dried full leather of China Toad refined through modern pharmaceutical technology. It is an initiative and exclusive product in China for curing a variety of advanced cancer and chronic hepatitis B, and it has a particularly prominent efficacy for hepatitis B virus carriers. “Gold Cinobufotalin” is presently produced in three formulations of injection liquid, oral liquid, and tablets, all of which have been classified as State Protected Medicine in China. In the Development of Traditional Chinese Medicine Prescription Drugs Category Development Plans, CR Sanjiu has set “Gold Cinobufotalin” as one of the core species, and determined to develop it into a strong brand for anti-tumor medicine and the standard setter for medicines of cinobufotalin in China. At present, in order to internationalize “Gold Cinobufotalin” as soon as possible, the company has carried out technical cooperation with the research institutions home and abroad, such as Anderson Cancer Center of United States, University of Tokyo of Japan, National Research Center in Complementary and Alternative Medicine in Norway, Zhejiang University and other domestic and foreign research institutions on the component analysis, production processes, quality control standards, mechanisms of action, clinical re-evaluation and adverse reactions resolution. CR Jinchan has also made efforts to improve the structure of product varieties to further enrich the formulations of Gold Cinobufotalin, and strive to build the company into the production base of leading anti-tumor medicine and Chinese medicine granules in the next five years.